Share

Medtronic plc (MDT.NYSE) AI OPINIONS & ADVISOR ANALYSIS

Read and compare the 14 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 20 September 2026Deep analysis 20 September 2026

Publisher

Russlan Ramdowar

25 min readAudit All Past Forecasts

14 AI Advisor Reports

Select an advisor report.

SynthesizerCombines all advisor views

Synthesis of 14 independent opinions

Diversity of ModelsSame approach, varied models

Diversity of FrameworksDifferent investing styles

AI Researcher

Opus 5

Universal Investor AI

The Polymath Framework

Model rating

Buy

5-Year Return Est.

+70.3%

Includes 2.82% annual net dividend contribution

1. Investment Thesis — Base Case

The central tension is credibility. Medtronic has spent a decade being a 4-5% grower wearing a premium multiple, and the market stopped believing the growth story long before it started working. The evidence now points the other way: roughly 7% underlying organic growth, a raised fiscal 2027 guide of $5.94-6.00, a cash-generative 15% free-cash-flow margin, and a split-off that retires 4-5% of shares at a 7% discount [1][11]. The base case is unglamorous compounding, earnings-led rather than multiple-led, interrupted by an optical revenue decline when Diabetes deconsolidates in fiscal 2028.

Fiscal 2027 non-GAAP EPS of $5.94-6.00 compounding high single digits toward roughly $8.30 by fiscal 2031.
At $92.10 the shares trade near 15.4x that guide; holding 16x implies about $135.
Cross-check: 5.2% TTM free-cash-flow yield plus 3% dividend funds the path without multiple expansion.

Historical prices and published forecast

Observed price
Published advisor forecast

Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.

View chart values

Historical prices and published forecast — published chart values
Series	Date	Value (USD)
Observed price	2021-09-14	130
Observed price	2021-10-01	126
Observed price	2021-10-10	124
Observed price	2021-10-31	121
Observed price	2021-11-05	122
Observed price	2021-11-26	111
Observed price	2021-12-09	113
Observed price	2021-12-18	102
Observed price	2021-12-27	104
Observed price	2022-01-13	109
Observed price	2022-01-22	105
Observed price	2022-02-04	103
Observed price	2022-02-17	103
Observed price	2022-03-06	107
Observed price	2022-03-15	106
Observed price	2022-04-05	111
Observed price	2022-04-10	112
Observed price	2022-05-01	103
Observed price	2022-05-19	104
Observed price	2022-05-27	98.9
Observed price	2022-06-01	97.7
Observed price	2022-06-18	88.3
Observed price	2022-07-01	91.2
Observed price	2022-07-10	89.0
Observed price	2022-07-23	90.2
Observed price	2022-08-13	95.0
Observed price	2022-08-18	95.1
Observed price	2022-09-04	86.6
Observed price	2022-09-13	90.5
Observed price	2022-09-30	81.2
Observed price	2022-10-09	82.4
Observed price	2022-10-30	87.3
Observed price	2022-11-04	83.2
Observed price	2022-11-25	79.1
Observed price	2022-12-13	80.0
Observed price	2022-12-17	76.8
Observed price	2022-12-26	77.6
Observed price	2023-01-12	80.3
Observed price	2023-01-21	80.0
Observed price	2023-02-03	85.6
Observed price	2023-02-16	84.4
Observed price	2023-03-09	78.3
Observed price	2023-03-14	78.4
Observed price	2023-03-18	80.2
Observed price	2023-04-09	80.6
Observed price	2023-04-30	90.8
Observed price	2023-05-05	90.5
Observed price	2023-05-26	85.3
Observed price	2023-05-30	82.9
Observed price	2023-06-17	88.3
Observed price	2023-07-08	86.5
Observed price	2023-07-13	88.0
Observed price	2023-07-26	90.2
Observed price	2023-08-08	82.4
Observed price	2023-08-29	82.1
Observed price	2023-09-07	80.1
Observed price	2023-09-16	81.7
Observed price	2023-10-03	76.5
Observed price	2023-10-07	74.9
Observed price	2023-10-29	70.2
Observed price	2023-11-11	71.4
Observed price	2023-11-24	78.5
Observed price	2023-11-28	79.0
Observed price	2023-12-16	82.8
Observed price	2023-12-24	82.3
Observed price	2024-01-11	87.1
Observed price	2024-02-01	87.6
Observed price	2024-02-10	85.7
Observed price	2024-02-19	85.5
Observed price	2024-02-27	83.5
Observed price	2024-03-24	83.6
Observed price	2024-04-02	85.5
Observed price	2024-04-06	83.9
Observed price	2024-04-15	79.4
Observed price	2024-05-07	81.6
Observed price	2024-05-15	85.5
Observed price	2024-06-06	83.9
Observed price	2024-06-15	80.8
Observed price	2024-06-23	80.8
Observed price	2024-07-11	77.1
Observed price	2024-07-24	79.1
Observed price	2024-08-10	82.2
Observed price	2024-08-14	83.6
Observed price	2024-09-05	90.9
Observed price	2024-09-09	90.5
Observed price	2024-09-18	89.0
Observed price	2024-10-05	88.0
Observed price	2024-10-23	91.0
Observed price	2024-11-05	90.1
Observed price	2024-11-18	85.2
Observed price	2024-11-26	86.3
Observed price	2024-12-18	80.3
Observed price	2024-12-31	80.1
Observed price	2025-01-13	85.0
Observed price	2025-01-17	88.2
Observed price	2025-02-03	91.5
Observed price	2025-02-21	88.5
Observed price	2025-03-06	94.1
Observed price	2025-03-14	92.6
Observed price	2025-03-27	87.7
Observed price	2025-04-05	84.8
Observed price	2025-04-18	82.0
Observed price	2025-05-18	86.3
Observed price	2025-05-23	80.7
Observed price	2025-05-27	82.0
Observed price	2025-06-13	88.0
Observed price	2025-06-26	86.0
Observed price	2025-07-14	89.7
Observed price	2025-07-27	92.4
Observed price	2025-08-04	90.1
Observed price	2025-08-17	93.1
Observed price	2025-08-26	92.0
Observed price	2025-09-08	93.2
Observed price	2025-09-21	95.4
Observed price	2025-10-04	96.9
Observed price	2025-10-26	93.6
Observed price	2025-11-03	90.5
Observed price	2025-11-21	101
Observed price	2025-11-25	105
Observed price	2025-12-17	98.5
Observed price	2025-12-30	96.1
Observed price	2026-01-07	99.3
Observed price	2026-01-16	99.3
Observed price	2026-02-02	103
Observed price	2026-02-11	101
Observed price	2026-03-05	93.0
Observed price	2026-03-09	90.3
Observed price	2026-03-31	86.6
Observed price	2026-04-13	88.1
Observed price	2026-04-26	83.0
Observed price	2026-04-30	80.7
Observed price	2026-05-09	76.2
Observed price	2026-05-30	74.5
Observed price	2026-06-08	82.0
Observed price	2026-06-30	78.2
Observed price	2026-07-12	83.6
Observed price	2026-07-21	82.0
Observed price	2026-08-07	87.9
Observed price	2026-08-16	90.7
Observed price	2026-08-20	93.3
Observed price	2026-09-07	92.7
Observed price	2026-09-23	89.3
Observed price	2026-09-24	88.5
Observed price	2026-09-25	88.6
Published advisor forecast	2026-09-18	92.1
Published advisor forecast	2026-12-18	94.9
Published advisor forecast	2027-03-18	96.8
Published advisor forecast	2027-06-18	93.9
Published advisor forecast	2027-09-18	97.6
Published advisor forecast	2027-12-18	101
Published advisor forecast	2028-03-18	103
Published advisor forecast	2028-06-18	106
Published advisor forecast	2028-09-18	108
Published advisor forecast	2028-12-18	111
Published advisor forecast	2029-03-18	113
Published advisor forecast	2029-06-18	111
Published advisor forecast	2029-09-18	114
Published advisor forecast	2029-12-18	118
Published advisor forecast	2030-03-18	120
Published advisor forecast	2030-06-18	122
Published advisor forecast	2030-09-18	125
Published advisor forecast	2030-12-18	129
Published advisor forecast	2031-03-18	131
Published advisor forecast	2031-06-18	134
Published advisor forecast	2031-09-18	137

2. Scenarios & Signals

Bull case

The bull case activates when two independent engines fire together: renal denervation converts its CMS coverage into real procedure volume while Hugo wins general-surgery clearance. Suddenly Medtronic is not a single-franchise recovery but a three-platform growth story, holds above 7% into the 2030s, and mix pushes operating margin toward 21%. Investors then pay 18x rather than 15x forward earnings on a larger number, and the share retirement magnifies each incremental dollar. That combination produces returns well above the base path.

Bear case

The bear case begins the day pulsed-field ablation becomes a commodity. Boston Scientific and J&J force annual price erosion, Medtronic defends share by conceding margin, and group slides back to 4%. The fiscal 2028 reported revenue decline from deconsolidation then reads as confirmation rather than accounting, tariffs keep a $300 million annual bite in operating income, and a 5.5% 10Y removes the yield support. Earnings stagnate while the multiple compresses toward 12x, delivering a meaningful drawdown from today's price.

Current crowd narrative

The settled belief is that Medtronic is a permanently repaired but permanently pedestrian compounder: a 4-6% grower that finally beat, raised fiscal 2027 guidance to $5.94-6.00 and deserves a relief rally, nothing more [1]. Sell-side anchors on the decade-long 22-29x trailing band and treats the 13.7% headline as a one-week artefact to be discounted entirely. The MiniMed split-off is filed under housekeeping, not per-share arithmetic.

Alpha-gap assessment

The crowd modestly underestimates these shares. Two pieces of evidence do not appear in the consensus arithmetic. First, stripping the extra week's $570 million leaves roughly 7% underlying , not 4-5%, which is a regime change for this company [1][4]. Second, the exchange offer retires an estimated 4-5% of shares at a 7% discount without cash [9][11]. At 15.4x the guided fiscal 2027 non-GAAP with a 5.2% free-cash-flow yield, that combination is underpriced.

Convergence catalyst

The October 9 exchange-offer expiry is the trigger: a completed split-off delivers a visible share-count reduction and a clean, diabetes-free margin structure [11]. First observable sign of repricing is the November fiscal-Q2 print showing high-single-digit without the extra week, followed by consensus revisions higher.

Paywalled preview begins: Macro-regime alignment

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Sentiment and regime

Greed and fear sentiment: 0.1
Expected volatility regime: moderate
Convergence-cycle position: growing_awareness

Primary drivers

Primary drivers supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Cardiac Ablation's 88% Flywheel	The evidence chain starts here: Cardiac Ablation Solutions grew 88% worldwide, crossed $2 billion trailing revenue ahead of schedule and took nine points of US share [1][4]. Pulsed-field ablation is a genuine category shift, and Affera/Sphere-9 mapping locks in an installed base that generates recurring catheter pull-through. Growth decays mechanically as the base compounds, but the absolute dollars keep compounding group organic growth toward 7%.	Not available	+32.0%
Split OFF AS A Discounted Buyback	Medtronic is exchanging up to 225.4 million MiniMed shares for its own ordinary shares at a 7% discount, roughly $107.53 of MiniMed per $100 tendered, with pricing days 5-7 October 2026 [9][11]. This retires an estimated 4-5% of the 1.29 billion share count without cash. It is a real per-share transfer, not financial theatre, and it permanently lifts EPS arithmetic.	Not available	+16.0%
Shedding THE R&d Hungry Stepchild	Deconsolidating Diabetes removes a business with roughly double the R&D intensity of the remaining group, freeing capital for ablation, renal denervation, Altaviva and Hugo [13]. Group gross margin optics improve, capex-to-revenue near 5.2% should ease, and the tariff-exposed, lower-margin pump supply chain leaves the ledger. Operating margin near 17.8% has room toward the low twenties over the horizon, converting revenue growth into faster earnings growth.	Not available	+14.0%
Procedures Ignore THE OIL Price	Hip replacements, ablations and pacemaker implants do not track Brent at $103.87 or the Fed's 3.75-4.00% range. Medtronic's demand stream is demographic, procedural and largely reimbursed, which is why revenue grew every year through the 2026 energy shock and Q2 GDP deceleration to 1.5% SAAR. In a tightening regime where cyclical earnings quality is suspect, that defensiveness attracts capital and supports the multiple investors pay.	Not available	+13.0%

Primary frictions

Primary frictions supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
THE FIVE Percent Discount RATE Ceiling	US 10Y at 4.998% and a Fed median dot of 4.1% for both 2026 and 2027 cap what anyone will pay for a 3%-yielding, long-duration compounder. Medtronic's terminal-value-heavy cash flows discount harshly; the stock traded at 29x earnings in a zero-rate world and 22.6x trailing today. Persistent 3.4% CPI keeps the ceiling in place through at least 2027, limiting multiple expansion to earnings-led gains.	Not available	-10.0%
Pfa's Coming Price WAR	Boston Scientific's Farapulse and Johnson & Johnson's Varipulse are attacking the same electrophysiology pool, and J&J's Ottava robot targets Hugo's beachhead after an expected early-2026 FDA submission [20]. Pulsed-field ablation catheters will follow the classic medtech curve: rapid adoption, then annual ASP erosion. Medtronic's 88% growth rate cannot persist; the realistic outcome is share stability at falling prices, compressing the incremental margin on its best franchise.	Not available	-7.0%
THE Fy28 Optical Growth Scare	Removing roughly $2.8 billion of Diabetes revenue makes fiscal 2028 reported revenue decline even as organic growth holds near 7%. Screens and headline-driven allocators will read deconsolidation as deceleration. Layer on Medtronic's own record, ROE of 9.7% on a $93 billion asset base after a decade of acquisitions, and the market's scepticism about capital allocation is earned. Expect at least one valuation air pocket around the fiscal 2028 guide.	Not available	-5.0%
Tariffs AS A Permanent Gross Margin TAX	Replacement Section 301 duties of 10-12.5% across 60 economies survived the February 2026 IEEPA ruling, so the cost regime is structural, not transitory. Company guidance indicated tariffs could raise gross cost of goods by up to $950 million in fiscal 2026, with $200-350 million net after mitigation [23]. A $300 million net drag is roughly 4-5% of operating income, recurring, and only partly recoverable through pricing in reimbursed markets.	Not available	-5.0%

Tail opportunities

Tail opportunities supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Renal Denervation Finally GETS PAID	CMS finalised a national coverage determination for renal denervation on 28 October 2025, and from 1 January 2026 the device offset for the procedure is $0 when C1735 is reported with 0339T [15][17]. If hypertension centres scale through 2028-2029, Symplicity Spyral could approach a $1 billion franchise against the company's own $2-3 billion-by-2030 estimate [18]. That would add a visible second growth engine and justify a 17-18x forward multiple. It stays below 50% because physician workflow adoption, not reimbursement, is the binding constraint.	32.0%	+20.0%
HUGO Escapes THE Urology CAGE	Hugo was cleared 3 December 2025 for urologic procedures only, making Medtronic the first large medtech to field a US soft-tissue robot since Intuitive [19][20]. Clearance for general and gynecologic surgery, plausibly 2027-2028, would open roughly 80% of the addressable procedure pool and turn a capital-equipment curiosity into a recurring-instrument annuity. The market currently assigns Hugo near-zero value, partly because Medtronic has not disclosed installed base. Probability stays under 50% given regulatory timing and J&J's Ottava entry.	38.0%	+14.0%

Tail risks

Tail risks supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Electrophysiology Growth Cliff	If Boston Scientific and J&J convert PFA into a three-way commodity contest by 2028-2029, Medtronic's ablation growth collapses from 88% toward mid-single digits while catheter ASPs fall double digits annually. Group organic growth reverts to the 4-5% the market assumed in mid-2026, when the cap was $106.8 billion [6]. The forward multiple compresses from roughly 15x to 12-13x and the re-rating thesis dies. Probability under 50% because Affera mapping integration and the installed base create genuine switching friction.	33.0%	-24.0%
Yields Break FIVE AND STAY There	Should energy-driven inflation keep US headline CPI above 3.5% and push the 10Y durably above 5.5% in 2027-2028, income-substitute equities de-rate hard. Medtronic's 3% dividend loses its relative appeal against risk-free paper, and a 22.6x trailing multiple on slow-compounding GAAP earnings looks indefensible. The transmission is purely valuation, not demand: procedure volumes hold while the share price falls. It remains below 50% because Fed projections point to 4.1% policy rates, not a renewed inflation spiral.	28.0%	-20.0%

Step-by-step forecast path

Universal Investor forecast path for prediction task predrqst_batch_task__xrefsubjtskconf_65d64a35-1423-55e7-bdb4-0e67c2430381__sb7__20260920064920277661
Step	Forecast date	Step change	Projected value (USD)	Scenario rationale
1	December 18, 2026	+3.0%	94.89	Exchange offer expires October 9, retiring an estimated 4-5% of shares at a 7% discount; November fiscal-Q2 print tests whether organic growth holds near 7% without the extra week.
2	March 18, 2027	+2.0%	96.79	Fiscal-Q3 results in February confirm ablation momentum, but a Fed holding near 4% and a 10Y above 4.9% cap multiple expansion. Earnings arithmetic, not re-rating, drives the gain.
3	June 18, 2027	-3.0%	93.89	Late-May fiscal 2027 results arrive with a fiscal 2028 guide showing reported revenue declining as Diabetes deconsolidates. Screens read deceleration; a valuation air pocket opens despite intact organic growth.
4	September 18, 2027	+4.0%	97.64	The optical scare unwinds as the first clean post-split quarter shows high-single-digit organic growth and improved gross margin. Investors recalibrate to the smaller, faster, higher-margin Medtronic.
5	December 18, 2027	+3.0%	100.57	Renal denervation volumes begin appearing in Cardiovascular disclosures following the $0 device offset from January 2026. Early evidence of a second growth engine supports incremental multiple repair.
6	March 18, 2028	+2.0%	102.58	Inflation moderating toward 2.5% lets long yields ease modestly, helping income-substitute equities. Medtronic's 3% yield regains relative appeal, though competitive PFA pricing chatter limits enthusiasm.
7	June 18, 2028	+3.0%	105.66	Fiscal 2028 results show operating margin advancing past 19% on mix, with tariff mitigation offsetting the Section 301 drag. Margin expansion becomes the visible earnings driver.
8	September 18, 2028	+2.0%	107.78	Hugo submissions for general and gynecologic indications progress at FDA while J&J's Ottava commercialises. Option value accrues slowly; capital-equipment cycles remain constrained by hospital financing costs.
9	December 18, 2028	+3.0%	111.01	Ablation franchise annualises above $3 billion with catheter pull-through providing recurring revenue. Growth rate decays but absolute dollars compound, sustaining high-single-digit group organic growth.
10	March 18, 2029	+2.0%	113.23	Steady compounding quarter. Buyback resumes at scale given free-cash-flow margin near 16%, supporting per-share economics while the forward multiple sits in the mid-teens.
11	June 18, 2029	-2.0%	110.96	Competitive scare: evidence of double-digit PFA catheter ASP erosion from Boston Scientific and J&J pressures the electrophysiology margin narrative, prompting a modest de-rating despite volume growth.
12	September 18, 2029	+3.0%	114.29	Reassurance arrives as Affera mapping integration proves switching friction real; share holds and mix improves elsewhere. Neuroscience and structural heart offset electrophysiology price pressure.
13	December 18, 2029	+3.0%	117.72	Renal denervation approaches a meaningful revenue line as hypertension centres scale, validating the CMS coverage thesis. Consensus forward estimates move higher for the first time in the horizon.
14	March 18, 2030	+2.0%	120.08	A more accommodative rate regime, with policy rates below 3.5%, marginally lifts the valuation investors accept for long-duration medtech cash flows. Earnings growth continues to dominate returns.
15	June 18, 2030	+2.0%	122.48	Fiscal 2030 results show operating margin near 21% on the diabetes-free cost base. Cash conversion remains strong, funding dividend growth and consistent share retirement.
16	September 18, 2030	+2.0%	124.93	Hugo installed base finally disclosed with recurring-instrument revenue building. Contribution stays modest against a $40 billion base, but removes a long-standing informational blind spot.
17	December 18, 2030	+3.0%	128.67	Aging-demographic procedure volumes underpin mid-single-digit organic growth as the ablation surge normalises. Defensive earnings quality attracts allocation amid a maturing global expansion.
18	March 18, 2031	+2.0%	131.25	Compounding without drama. EPS approaching $8 supports the price at a stable mid-teens forward multiple; capital returns absorb the bulk of incremental free cash flow.
19	June 18, 2031	+2.0%	133.87	Pipeline attention shifts to next-generation neuromodulation and structural heart. Incremental gains reflect steady execution rather than re-rating, consistent with a mature medtech growth profile.
20	September 18, 2031	+2.0%	136.55	Horizon close with fiscal 2031 earnings power near $8.30 per share. Price near $136 implies roughly 16x forward, an unremarkable multiple for a resilient 6% organic grower.

Advisor and configuration

Advisor: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release
Persona: Universal Investor
Archetype: The Polymath
Model: 2026-07-24 release
Provider: Anthropic
Mode: RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity
Task configuration: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release__equity__json__extnd_invest_thesis_4q_alphassym__ts_num_desc__h5y_s3m__var1__researcher__standard_creativity_high_thinking__batch
Forecast horizon: 5 year
Forecast steps: 20 steps of 3 month
Assembly type: Balanced Assembly
Assembly name: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release RESEARCHER Forecast Assembly
Input format: inmemory_base_placeholders__latest_eod_close_price_with_stats_and_fundamentals__var1
Output format: Equity Extended Investment Thesis (4 Quadrants and Alpha Asymmetry) + Pct Change Timeseries for Close Price with Rationale, (5Y Quarterly)

Read the complete Universal Investor advisor methodology

Configuration components

aiassmprmtcmpnt_b995bbe2-6a15-55be-a576-525904f696e8
aiassmprmtcmpnt_c55d1851-d218-5d30-b83b-54bbda31e2ee
aiassmprmtcmpnt_930157b1-05d7-5699-bf0a-738645ee42fd
aiassmprmtcmpnt_3c0c459a-0d4a-50ca-87df-c172ec5618aa
aiassmprmtcmpnt_8115cc2a-d418-54b1-a616-49dfa91195f4

Research sources

[1]Medtronic reports first quarter fiscal 2027 results; delivers broad-based portfolio performance and raises fiscal 2027 guidance - Sep 1, 2026news.medtronic.com
[2]Medtronic plc - Form 8-K - FY2026sec.gov
[3]Documentsec.gov
[4]Medtronic PLC (MDT) (Q1 2027) Earnings Call Highlights: Strong Revenue Growth and Raised ...finance.yahoo.com
[5]Medtronic plc - Form 10-Q - FY2026sec.gov
[6]Medtronic (MDT) to Announce Q1 FY2027 Earnings on August 18gurufocus.com
[7]Medtronic plc - Form 8-K - FY2026sec.gov
[8]Medtronic Launches Exchange Offer to Complete MiniMed Separationsurgicalroboticstechnology.com
[9]Medtronic launches exchange offer to split off MiniMed stake - Financial Newsfinancial-news.co.uk
[10]Medtronic Advances Diabetes Spin-Off with Share Exchange - TipRanks.comtipranks.com
[11]Medtronic Opens MiniMed Split-Off Exchange Offer With 7% Discount – Securities.iosecurities.io
[12]Medtronic outlines MiniMed share exchange offer | MDT SEC Filing - Form 425stocktitan.net
[13]Medtronic begins final steps to separate MiniMed | MedTech Divemedtechdive.com
[14]CMS grants NCD for renal denervation, benefiting Medtronic, Recor | MedTech Divemedtechdive.com
[15]CMS finalizes renal denervation coverage that benefits Medtronic, Recormassdevice.com
[16]Renal Denervation (RDN) Reimbursement | Medtronicmedtronic.com
[17]Symplicity Spyral™ renal denervation system Overview ...medtronic.com
[18]Medtronic receives FDA approval for renal denervation device | MedTech Divemedtechdive.com
[19]FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures | Urology Timesurologytimes.com
[20]Medtronic’s Hugo surgical robot earns FDA clearance | MedTech Divemedtechdive.com
[21]Medtronic Hugo Robotic Surgery System: New 2026 FDA-Cleared Challenger Enters US Market | Medaptlymedaptly.com
[22]Earnings call transcript: Medtronic beats Q1 2026 estimates and lifts outlook By Investing.cominvesting.com
[23]Medtronic Diabetes Business Separation - iData Researchidataresearch.com
[24]Medtronic reports first quarter fiscal 2027 results; delivers broad-based portfolio performance and raises fiscal 2027 guidance - BioSpacebiospace.com
[25]Medtronic Diabetes to submit patch pump to FDA by fall 2026drugdeliverybusiness.com

Back to advisor navigation

End of the paywalled preview

The excerpt from Macro-regime alignment to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Other AI Advisor reports — limited previews

Sherlock Holmes — RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity

Gemini 3.8 Flash

Limited structural preview, provided as simplified HTML. The complete report contains substantially more research: its investment thesis; bull and bear scenarios; macro-regime analysis; drivers, risks and opportunities; quarterly forecast tables and rationale; references and published configuration. Those findings and datasets are not included here. Sign in with the required subscription to open this advisor's full report.